Australia's most trusted
source of pharma news
Thursday, 06 February 2025
Posted 3 February 2025 PM
Telix will spend up to $372 million (US$230 million) to buy most of the assets of US-based ImaginAb.
In the deal Telix will receive a pipeline of next-generation therapeutic candidates, a proprietary novel biologics technology platform, and a state-of-the art research facility in Los Angeles.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.